Investigational drug · Phase 3
Istaroxime
Also called: PST2744
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiogenic Shock.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "Istaroxime"
First trial start
2024
Jun 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Istaroxime", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiogenic Shock
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Istaroxime" as an intervention, largest first.
- Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic ShockPivotal-lookingRecruiting
Seismic Pharmaceuticals Operations LLCIndustry
NCT07583446 · 600 participants (planned) · Start Sep 9, 2026 · Primary completion Dec 2028
Drug: istaroxime; placebo · For: Cardiogenic Shock
Sites: Yerevan, Armenia
- A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic FunctionPivotal-lookingCompleted
sigma-tau i.f.r. S.p.A.Industry
NCT00616161 · 120 participants · Start Aug 2006 · Primary completion Jul 2007
Drug: Istaroxime; Istaroxime and 2 more · For: Heart Failure
- The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart FailurePivotal-lookingCompleted
Windtree TherapeuticsIndustry
NCT02617446 · 120 participants · Start Dec 2015 · Primary completion Aug 14, 2018
Drug: Placebo; Istaroxime · For: Acute Decompensated Heart Failure
Sites: Lanzhou, China; Wuhan, China; Nanjing, China · 11 sites in all
Windtree TherapeuticsIndustry
NCT04325035 · 90 participants · Start Sep 28, 2020 · Primary completion Sep 26, 2024
Drug: Istaroxime; Placebo · For: Cardiogenic Shock
Sites: Boston, Massachusetts; Capital Federal, Argentina; Rosario, Argentina · 13 sites in all
Lee's Pharmaceutical LimitedIndustry
NCT02477449 · 32 participants · Start Mar 2015 · Primary completion Oct 2015
Drug: istaroxime; 9% Saline (NS) · For: Healthy
Sites: Beijing, China
Benjamin LevineAcademic, hospital or other
NCT02772068 · 26 participants · Start Sep 15, 2015 · Primary completion Dec 1, 2018
Drug: Istaroxime · For: Heart Failure, Congestive
Sites: Dallas, Texas
- A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage CActive, not recruiting
Windtree TherapeuticsIndustry
NCT05975021 · 20 participants · Start Jun 1, 2024 · Primary completion Jul 28, 2025
Drug: Istaroxime; Placebo · For: Cardiogenic Shock
Sites: Boston, Massachusetts; Portland, Oregon; Capital Federal, Argentina · 15 sites in all
Debiopharm International SAIndustry
NCT00869115 · 0 participants · Start Jun 2009
Drug: Istaroxime; Istaroxime and 2 more · For: Heart Failure
Debiopharm International SAIndustry
NCT00838253 · 0 participants · Start Jun 2009
Drug: Istaroxime; Istaroxime and 2 more · For: Heart Failure
Newest research
PubMed records naming it or its code names, newest first.
- Clinical effects of istaroxime in acute heart failure and cardiogenic shock: A patient-level pooled analysis of four phase II randomized clinical trials.
Pagnesi M, Davison B, Cotter G, et al. · J Card Fail 2026
- Early changes in dyspnea with 24-h istaroxime infusion among patients with acute heart failure.
Pagnesi M, Cotter G, Davison B, et al. · J Cardiovasc Med (Hagerstown) 2026
- Istaroxime's Effect on Hemodynamics and Arrhythmias in Cardiogenic Shock: A Pooled Analysis of SEISMiC Trials.
Biegus J, Niewinski P, Pagnesi M, et al. · JACC Heart Fail 2026
- Istaroxime in Acute Heart Failure and Early Cardiogenic Shock: A Calcium-Cycling Approach to Inotropic Therapy.
Krasiska B, Maria Raffa G, Pisano C, et al. · Int J Mol Sci 2026
- Early management of acute heart failure.
Miró Ò, Polyzogopoulou E, Parissis J · Curr Opin Crit Care 2026
- Istaroxime - update of data in early cardiogenic shock and decompensated heart failure.
Florek K, Zimoch W, Biegus J · Expert Opin Investig Drugs 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.